Key Highlights
- Shares fell 0.82% to USD 80.13 on relative Volume of 1.89.
- Third-quarter Revenue was USD 2,391 million versus USD 2,422 million.
- Attributable Net Income was USD 591 million, or USD 1.44 per diluted share.
- Adjusted Earnings Per Share guidance was raised to USD 6.25 to USD 6.35.
Zoetis (NYSE:ZTS) shares traded at USD 80.13 on November 20, 2026, down 0.82%, with a relative volume at time of 1.89. The company has given no reason for the heavy trading. It filed its Quarterly Report and held its Earnings Call on November 5, and on November 19 it announced a USDA license for a chicken vaccine. Those items are reported here separately from the trading, and no link between them is claimed.
Zoetis Inc. is a Delaware corporation based in Parsippany, New Jersey. It discovers, develops, makes and sells medicines, vaccines, diagnostics, biodevices and genetic tests for animal health, serving veterinarians, pet owners and livestock producers worldwide. It runs two geographic segments, the United States and International, and reports revenue by companion animal and livestock species.
USDA License for a Poultry Vaccine
On November 19, Zoetis announced that it had received a USDA license for its Poulvac Procerta HVT-ND-ILT Vaccine for chickens. Poultry revenue was USD 108 million in the third quarter versus USD 106 million a year earlier.
The Third Quarter
Revenue was USD 2,391 million versus USD 2,422 million. Cost of sales was USD 698 million versus USD 697 million, and Research and Development expense was USD 174 million versus USD 175 million. Selling, general and administrative expense was USD 582 million in both periods.
Restructuring and certain Acquisition and divestiture costs were USD 43 million versus USD 4 million. Net interest expense was USD 62 million, and other deductions, net, were USD 72 million versus other income, net, of USD 12 million.
Pretax income was USD 729 million versus USD 886 million, and the tax provision was USD 138 million versus USD 165 million. Net income attributable to Zoetis was USD 591 million versus USD 721 million. Diluted Earnings per Share were USD 1.44 versus USD 1.63, on weighted-average diluted shares of 411.6 million versus 443.2 million.
Segments and Species
U.S. segment revenue fell by USD 76 million, or 6%, while International segment revenue rose by USD 42 million, or 4%. Companion animal revenue was USD 1,565 million versus USD 1,650 million, including USD 1,492 million from dogs and cats versus USD 1,581 million. Livestock revenue was USD 797 million versus USD 746 million.
Nine Months, Balance Sheet and Cash Flow
Nine-month revenue was USD 7,121 million versus USD 7,094 million. Net income attributable to Zoetis was USD 1,883 million versus USD 2,049 million, and diluted earnings per share were USD 4.51 versus USD 4.60. Dividends declared per share were USD 1.060 versus USD 1.000.
Cash was USD 1,333 million versus USD 2,450 million at December 31, 2025. Total Assets were USD 15,088 million versus USD 15,490 million, and long-term Debt was USD 8,299 million versus USD 9,042 million. Equity was USD 3,303 million versus USD 3,415 million.
Operating activities provided USD 1,880 million versus USD 2,056 million, while financing activities used USD 2,371 million versus USD 1,375 million.
2026 Guidance
On the November 5 call, management narrowed 2026 revenue guidance to USD 9.22 billion to USD 9.32 billion. It raised adjusted net income guidance to USD 2.6 billion to USD 2.64 billion and adjusted diluted earnings per share guidance to USD 6.25 to USD 6.35. Management also said it had returned USD 2.4 billion through Buybacks and dividends by the end of the third quarter and would update its shared financial metrics on the fourth-quarter call.
What to Watch Next for Zoetis
The company has given no reason for the November 20 trading, and its results, guidance and license news came earlier. The reported record shows lower revenue and earnings alongside a narrowed revenue range and a raised earnings range. The fourth-quarter call is the next scheduled update.






Please wait processing your request...